Evidence map›Paper›PMID 42088395›Full record

ArticleInternational journal of nanomedicine2026

Yung-Chieh Chang, Wei-Lun Huang, Wu-Chou Su, Euphemia Leung, Fong-Yu Cheng, Chun Hei Antonio Cheung

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yung-Chieh ChangTMU Research Center of Cancer Translational Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.ORCID 0000-0002-8699-2834
Wei-Lun HuangCenter of Applied Nanomedicine, National Cheng Kung University, Tainan, Taiwan.
Wu-Chou SuCenter of Applied Nanomedicine, National Cheng Kung University, Tainan, Taiwan.
Euphemia LeungAuckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Grafton, Auckland, New Zealand.ORCID 0000-0002-6932-3188
Fong-Yu ChengDepartment of Chemistry, College of Natural Science and Engineering, Chinese Culture University, Taipei, Taiwan.ORCID 0000-0002-7826-0676
Chun Hei Antonio CheungDepartment of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.ORCID 0000-0003-4181-1435

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: BIRC5 (survivin), an inhibitor of apoptosis protein, is overexpressed in most tumors and is associated with drug resistance, proliferation, and metastasis, while being largely undetectable in normal differentiated tissues. This unique expression pattern makes BIRC5 an exceptionally selective therapeutic target, offering the potential to maximize anticancer efficacy while minimizing systemic toxicity to healthy tissues. However, few BIRC5-targeted agents have advanced to late-stage clinical trials. Methods: We developed two nanodrug formulations using poly-L-lysine-modified NH Results: The PL-MNPs delivered plasmids driven by the Conclusion: These findings establish that the easily synthesized PL-MNP-p

Indexed as

Antineoplastic AgentsInhibitor of Apoptosis ProteinsMagnetite NanoparticlesNeoplasmsSurvivinAnimalsATP Binding Cassette Transporter, Subfamily BCell Line, TumorDrug Resistance, NeoplasmHumansIndoleamine-Pyrrole 2,3,-DioxygenasePromoter Regions, GeneticXenograft Model Antitumor AssaysABCB1 protein, humanAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BBIRC5 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseInhibitor of Apoptosis ProteinsMagnetite NanoparticlesSurvivinABCB1BIRC5ERBB2HER2iron oxide nanoparticlesurvivin

Identifiers

PMID42088395
PMCPMC13136908

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.